Anti-VEGF Therapy — Competitive Intelligence Brief

Anti-VEGF Therapy (Anti-VEGF Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor. Area: Oncology, Ophthalmology.

phase 3 VEGF inhibitor VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors Oncology, Ophthalmology Small molecule

Target snapshot

Anti-VEGF Therapy (Anti-VEGF Therapy) — Hoffmann-La Roche. Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-VEGF Therapy TARGET	Anti-VEGF Therapy	Hoffmann-La Roche	phase 3	VEGF inhibitor	VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors
intravitreal Anti-VEGF injection	intravitreal Anti-VEGF injection	Seoul National University Bundang Hospital	marketed	VEGF inhibitor	VEGF (Vascular Endothelial Growth Factor)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Macugen (Pegaptanib Sodium)	Macugen (Pegaptanib Sodium)	Retina Institute of Hawaii	marketed	VEGF inhibitor / Aptamer	VEGF165 (Vascular Endothelial Growth Factor)
anti-VEGF agent	anti-VEGF agent	Medical University of Vienna	marketed	Anti-angiogenic agent (VEGF inhibitor)	VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors
Subconjunctival Bevacizumab	Subconjunctival Bevacizumab	Grewal Eye Institute	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor class)

1. Hoffmann-La Roche · 2 drugs in this class
2. Genentech, Inc. · 1 drug in this class
3. Genzyme, a Sanofi Company · 1 drug in this class
4. Innostellar Biotherapeutics Co.,Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Eli Lilly and Company · 1 drug in this class
8. Seoul National University Bundang Hospital · 1 drug in this class